- Book
- November 2024
- 848 Pages
- Book
- September 2023
- 512 Pages
- Book
- July 2023
- 304 Pages
- Book
- September 2022
- 208 Pages
- Book
- March 2022
- 896 Pages
- Book
- January 2022
- 400 Pages
- Book
- September 2021
- 432 Pages
- Book
- April 2021
- 464 Pages
- Book
- March 2020
- 400 Pages
- Book
- February 2018
- 400 Pages
- Book
- January 2018
- 904 Pages
- Book
- November 2017
- 628 Pages
- Book
- March 2016
- 376 Pages
- Book
- November 2013
- 744 Pages

The Monoclonal Antibodies market is a subset of the biotechnology industry that focuses on the production and use of monoclonal antibodies (mAbs). mAbs are laboratory-produced proteins that are designed to bind to specific targets, such as proteins, cells, or tissues. They are used in a variety of applications, including diagnostics, therapeutics, and research.
The market for mAbs is growing rapidly, driven by advances in biotechnology and the increasing demand for personalized medicine. mAbs are used in a variety of treatments, including cancer, autoimmune diseases, and infectious diseases. They are also used in research to develop new treatments and to improve existing treatments.
The market for mAbs is highly competitive, with many companies offering a wide range of products. Major players in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are investing heavily in research and development to develop new mAbs and to improve existing products.
In conclusion, the Monoclonal Antibodies market is an important part of the biotechnology industry, with many companies investing heavily in research and development to develop new products and improve existing treatments. Major players in the market include AbbVie, Amgen, AstraZeneca, Show Less Read more